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Abstract: Noradrenaline has long played a key role in the way the etiology of depression is
conceptualized and in the mechanism of action of many current antidepressants. Tricyclic
antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), serotonin-noradrenaline
reuptake inhibitors (SNRIs), selective noradrenaline reuptake inhibitors (NRIs), the
noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazapine, and many
atypicals, like mianserin and bupropion, influence, at least in part, central noradrenergic
function. Enhancement of noradrenergic function may be particularly helpful in patients with
melancholia. However, while noradrenaline will continue to be a target for research into the
etiology and treatment of depression, it is unlikely that antidepressants acting solely on
noradrenaline will be pursued.
Keywords: alpha2-adrenoceptors, antidepressants, depression, noradrenaline, reuptake
Introduction
The notion that noradrenaline plays a key role in the etiology of depression and in
the mechanism of action of antidepressants dates from the earliest days of the
psychopharmacology era, and formed the basis for the catecholamine hypothesis of
affective disorders (Schildkraut 1965). It was based on clinical observations that
drugs that depleted noradrenaline and other brain monoamines lowered mood, while
agents that enhanced the availability of brain monoamines improved mood and
reversed the symptoms of depression. The original catecholamine hypothesis was
soon modified to include a complementary role for serotonin as it was realized that
traditional antidepressants, such as the tricyclics (TCAs) and the monoamine oxidase
inhibitors (MAOIs), increased the levels of both noradrenaline and serotonin in the
brain by blocking their reuptake or metabolic degradation, respectively (Coppen
1967). There are currently a large number of effective antidepressants of various
classes, diverse structures, and different mechanisms of action available for clinical
use (Table 1). Many of the original TCAs of the first generation were aselective in
neurochemical action in that they inhibited reuptake of both monoamines, although
desipramine, nortriptyline, and protriptyline were selective for noradrenaline, and
clomipramine was somewhat selective for serotonin. For many years, maprotiline
and viloxazine represented the last selective inhibitors of noradrenaline reuptake in
an era that was dominated by research on the role of serotonin in depression and the
development of selective serotonin reuptake inhibitors (SSRIs) as antidepressants
(Pinder et al 1977a, 1977b). Although noradrenaline still had its place in the
mechanism of action of the α2-adrenoceptor antagonist mianserin, many of the otherNeuropsychiatric Disease and Treatment 2005:1(1) 4
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early second generation antidepressants such as trazodone,
nefazodone, and the various SSRIs were based upon
serotonergic mechanisms (Pinder and Wieringa 1993).
While second generation antidepressants like the SSRIs have
enjoyed wide popularity due to their more selective
pharmacology and consequent improved tolerability and
lesser toxicity than their first generation counterparts, there
have been lingering doubts about their efficacy and onset
of action, particularly in the more severely depressed and
melancholic patients (Anderson 2000). The introduction of
newer second generation antidepressants, like the serotonin
noradrenaline reuptake inhibitors (SNRIs), exemplified by
venlafaxine, and the noradrenergic and specific serotonergic
antidepressant (NaSSA) mirtazapine, has demonstrated that
it is possible to regain the dual pharmacological action and
accompanying efficacy of the TCAs, while retaining the
greater tolerability and lesser toxicity of the SSRIs
(Nierenberg 2001; Smith et al 2002).
Enhancing central noradrenergic
function in depression
Noradrenaline as a specific target for treating depression,
as opposed to being part of a multiple target approach, has
become more fashionable in recent years with the
development of the selective noradrenaline reuptake
inhibitors (NRIs), eg reboxetine (Brunello et al 2002). In
the clinical setting, selective NRIs may be advantageous in
terms of short- and long-term efficacy in both moderate and
severe depression, while acting to improve energy, interest,
and motivation in depressed patients. However, like earlier
tricyclic examples of the genre, such as desipramine,
nortriptyline, maprotiline, and lofepramine (Table 1), and
unlike the dual-action SNRIs and mirtazapine, the efficacy
of reboxetine is not superior to that of SSRIs (Brunello et al
2002). Reboxetine is not yet approved in the USA as a result
of a series of failed clinical trials in which neither it nor the
active reference antidepressant were shown to be statistically
significantly different in efficacy from placebo. A similar
fate befell an earlier NRI, the tetracyclic Org 4428 (Pinder
and Wieringa 1993; Niklson et al 1997). Such failures have
prompted proposals to improve the ways in which clinical
trials are performed to evaluate the efficacy and onset of
action of new antidepressants (Katz et al 2002; Montgomery
et al 2002). Reboxetine is an example of the designer’s
approach to new antidepressants; it has a structure not
dissimilar to that of the older non-tricyclic NRI viloxazine,
without the structural features that are associated with
classical TCA-like side effects (Pinder 1997, 2001). It may
represent the last in a long line of NRIs for depression
(Pinder and Wieringa 1993), since there do not appear to be
any more of its ilk in clinical development at this time
(Andrews and Pinder 2001). Atomoxetine, like reboxetine,
is a highly selective NRI that was previously in development
as tomoxetine for depression (Pinder and Wieringa 1993),
and has been reincarnated as a treatment for attention deficit
hyperactivity disorder (ADHD) (Allen and Michelson
2002).
In addition to inhibiting the reuptake of noradrenaline,
there are other ways to enhance its synaptic availability. The
most notable is by blocking the α2-noradrenergic receptors
located at the cell body, which control cell firing, or those
at the synaptic terminal, which act as autoreceptors to
regulate release. Two currently available antidepressants,
mianserin and mirtazapine, do this as part of multiple
pharmacological actions. The more potent α2-adrenoceptor
Table 1 Currently available antidepressantsa
Group Drug Group Drug
TCAs Amitriptyline MAOIs Iproniazid
Amoxapine Isocarboxazid
Butriptyline Moclobemideb
Clomipramine Phenelzine
Desipramine Tranylcypromine
Dibenzepin
Dimetacrin SSRIs Citalopram
Dothiepin Escitalopram
Doxepin Fluoxetine
Imipramine Fluvoxamine
Iprindole Paroxetine
Lofepramine Sertraline
Maprotiline
Melitracen NaSSA Mirtazapine
Nortriptyline
Opipramol NRIs Reboxetine
Protriptyline Viloxazine
Trimipramine
SNRIs Duloxetine Atypicals Bupropion
c
Milnacipran Mianserin
Venlafaxine Nefazodone
Trazodone
a Many of these drugs are either not available in the USA or are approved for
indications other than depression.
b Moclobemide is the only marketed example of a reversible inhibitor of the
A-form of MAO (RIMA).
c Not currently available in Europe as antidepressants.
Abbreviations: TCAs, tricyclic antidepressants; SNRIs, serotonin-noradrenaline
reuptake inhibitors; MAOIs, monoamine oxidase inhibitors; SSRIs, selective
serotonin noradrenaline reuptake inhibitors; NaSSA, noradrenergic and specific
serotonergic antidepressant; NRIs, selective noradrenaline reuptake inhibitors.Neuropsychiatric Disease and Treatment 2005:1(1) 5
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antagonist idazoxan acts more selectively, but it has not been
convincingly shown to be antidepressant (Nutt and Pinder
1996). Of these three agents, only mirtazapine additionally
enhances central serotonergic function via stimulation of
facilitatory α1-adrenoceptors located on the cell bodies of
raphe neurons and blockade of α2-heteroreceptors located
on serotonergic nerve terminals, thereby endowing it with
the familiar dual action upon both neurotransmitters (De
Boer et al 1996). As with NRIs the development of new
selective α2-adrenoceptor antagonists for depression has
effectively stopped (Table 2). There is still some interest in
mimicking the dual action of mirtazapine by combining α2-
antagonism with other antidepressant-like pharmacology in
the same molecule, eg 5-HT1A-agonism (sunepitron), and
with SSRI (A 80426) or NRI (napitane) properties. Another
putative antidepressant, napamezole, combines α2-
antagonism with inhibition of the reuptake of three
monoamines – noradrenaline, serotonin, and dopamine.
Inconclusive efficacy data have been reported for many of
these compounds, and none of them seem to be in active
clinical development (Nutt and Pinder 1996; Andrews and
Pinder 2001).
The future for noradrenergic
antidepressants
Is there a role for a pure noradrenergic drug in the treatment
of depression (Montgomery 1997)? This question is
particularly pertinent in an era when dual-action
antidepressants affecting both noradrenergic and
serotonergic systems, including the newly approved SNRI
duloxetine, have demonstrated faster and more substantial
effects than SSRIs on response and remission. Moreover,
research on new antidepressants has largely moved away
from monoamines and their receptors to focus on
neurokinins, excitatory amino acids, neuronal plasticity,
gene transcription factors, and the hypothalamic-pituitary-
adrenal (HPA) axis (Skolnick 1997; Andrews and Pinder
2001; Pinder 2001). Furthermore, there is some evidence
that combining noradrenergic agents like desipramine or
mianserin with an SSRI to make a two-component dual-
action treatment actually improves response (see Andrews
and Pinder 2001). Nevertheless, the single-action SSRIs as
a group are still very widely used, while the latest
antidepressant introductions include not only duloxetine but
also the SSRI escitalopram (Table 1).
There is substantial preclinical and clinical evidence that
noradrenaline plays a key role in the etiology of depressive
disorders (Nutt and Pinder 1996; Leonard 1997; Brunello
et al 2002). Perhaps the most compelling arguments come
from depletion studies in recently remitted depressed
patients. Those patients who responded to, and continued
to take, NRIs were more vulnerable to transient reversal of
their response when given the catecholamine depleter α-
methyl-para-tyrosine (AMPT). Responders to SSRIs were
more vulnerable to tryptophan depletion, which reduces
brain serotonin (Delgado et al 1997). The implication that
there may be distinct roles for noradrenaline and serotonin
in depression is not, however, entirely borne out by later
observations from the same research group. Responders to
the dual-action NaSSA mirtazapine were as likely to
experience transient deterioration in mood when receiving
either alpha-methyl-para-tyrosine (AMPT) or undergoing
tryptophan depletion (Delgado et al 2002). Furthermore,
the roles of the central noradrenergic and serotonergic
systems may be inextricably linked in the etiology of
depression, and in the mechanism of action of
antidepressants both in the hippocampus (Mongeau et al
1997) and frontal cortex (Millan et al 2000). Even reboxetine
seems to have an effect upon serotonergic neurotransmission
in rat hippocampus, activating postsynaptic 5-HT1A receptors
by a desensitization of α2-adrenergic heteroreceptors
resulting from sustained inhibition of noradrenaline reuptake
(Szabo and Blier 2001).
Opportunities do exist to design more specific agents to
affect noradrenergic function in depression (Nutt and Pinder
Table 2 α2-adrenoceptor antagonists as antidepressants
Neurotransmitter
Compound Status affected
α2-antagonists with
multiple pharmacology
Mianserin Marketed NA
Mirtazapine Marketed NA/5-HT
Setiptiline Marketed in NA
Japan
Selective α2-antagonists
Idazoxan Stopped NA
Fluparoxan Stopped NA
Selective α2-antagonists with
additional antidepressant-like
pharmacology
Napitane Stopped NA
A 80426 Stopped NA/5-HT
Napamezole Stopped NA/5-HT/DA
Sunepitron Stopped NA/5-HT
Abbreviations: NA, noradrenaline; 5-HT, serotonin; DA, dopamine.Neuropsychiatric Disease and Treatment 2005:1(1) 6
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1996; Potter and Schmidt 2000). Thus, the fine molecular
structure of the noradrenaline transporter, which mediates
reuptake of the neurotransmitter, has long been characterized
as belonging to a large family of membrane proteins all
having 12 hydrophobic membrane spanning domains with
the amino terminal and the carboxyl terminal ends of the
polypeptide located intracellularly (Amara and Kuhar 1993).
The transcriptional gene for the noradrenaline transporter
has also been identified (Porzgen et al 1995), and human
polymorphisms are known (Zill et al 2002). Studies on
chimeric dopamine-noradrenaline transporters have
demonstrated that the binding domains for the tricyclic NRIs
nortriptyline and desipramine are located in a different
region from those for the neurotransmitter substrates (Giros
et al 1994). It may well be possible to design more
regioselective inhibitors of noradrenaline reuptake than have
presently been evaluated as antidepressants, and it is
interesting that contrary to expectations and previous
experience with most psychotropic drugs, compounds
lacking nitrogen in their structure are capable of inhibiting
the noradrenaline transporter (Madras et al 1996).
α2-adrenoceptors have also been cloned and
characterized (Bylund et al 1994). Three human genes
located on chromosomes 10, 2, and 4 encode unique α2-
adrenoceptor subtypes, which are characterized
pharmacologically as α2A, α2B, and α2C, respectively. The
α2D-subtype, found in the rat and other animal species but
not in humans, seems to be a species variant of the human
α2A-adrenoceptor. It is likely that noradrenergic neurons
express predominantly the same gene across all mammalian
species, the α2A/D-ortholog, to control transmitter release
through presynaptic autoreceptors. The α2A-adrenoceptor
is also the predominant subtype present in human blood
platelet and cortex (see Nutt and Pinder 1996). Neither the
tetracyclic antidepressants mianserin, setiptiline, and
mirtazapine, nor the more potent but putative antidepressants
idazoxan and fluparoxan are selective for any of the α2-
adrenoceptor subtypes, so it is entirely possible that highly
selective agents could be developed (Nutt and Pinder 1996;
Potter and Schmidt 2000).
Little research effort has gone into evaluating post-
synaptic noradrenergic agonists as antidepressants, unlike
the extensive investigations into postsynaptic 5-HT1A-
agonists. Two decades ago, the β2-adrenoceptor agonist
salbutamol and its more lipophilic cousin clenbuterol, which
are used as bronchodilators in the treatment of asthma,
enjoyed a brief vogue as putative antidepressants both in
their own right and as adjuncts to TCAs: both were found
wanting in efficacy and peripheral side effects (Potter and
Schmidt 2000). In more recent times, modafinil, an α1-
agonist and central stimulant indicated for the treatment of
narcolepsy, has become popular as an augmentation agent
when standard antidepressants give an insufficient
therapeutic response.
As a final note, the opportunities for finding new NRIs
and ligands for the various types of noradrenergic receptors
have been considerably enhanced by the modern
pharmaceutical technologies of combinatorial chemistry and
high-throughput screening (Pinder 2001). While such
methods are potentially inhibitory to true innovation, in the
sense that the biological assays are simple and usually based
on known and proven technology, they are ideal for this
type of opportunity. Many very large and diverse chemical
libraries exist which could be screened in assays for the
noradrenaline transporter and the different types of
noradrenergic receptor. Any desired combination of such
properties is also possible.
Conclusions
There is no doubt that some effective antidepressants act
principally through central noradrenergic mechanisms, and
that noradrenaline plays an important role in the etiology of
depressive disorders. Antidepressants with a noradrenergic
component to their pharmacology may produce superior
efficacy in severely depressed patients and those with
melancholia, but there is no evidence that selective NRIs
are any better than SSRIs except possibly in the arena of
energy, interest, and motivation. Rather, it is the older dual-
action TCAs and their modern counterparts the SNRIs and
mirtazapine, which seem to have set the current standard in
faster onset of action and greater degrees of response and
remission.
Despite the recent flurry of interest in reboxetine, and
the undoubted opportunities that exist for designing new
NRIs and novel agents to affect noradrenergic receptors,
there are no new antidepressants on the horizon that act
principally through noradrenaline. There remains a stronger
interest in serotonin and its receptors than in noradrenaline.
Real innovation in antidepressant research is focusing on
other, non-monoamine approaches, including neurokinins,
excitatory amino acids, neuronal plasticity, gene
transcription factors, and the HPA axis. Whether it leads to
true third generation antidepressants, which will extend our
ability to treat depression more quickly in a greater
proportion of patients with improved rates of response and
remission, is still to be seen. Early indications are that theNeuropsychiatric Disease and Treatment 2005:1(1) 7
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first neurokinin antagonists are no faster or better than SSRIs
in efficacy, and may not be developed further, but that
glucocorticoid antagonists may be superior in psychotic
depression, melancholia, and in those patients with disturbed
cortisol. There is certainly a place in the armamentarium
for new antidepressants, but it is unlikely that they will be
agents that only enhance central noradrenergic function.
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